<DOC>
	<DOCNO>NCT01970033</DOCNO>
	<brief_summary>SP2086 new dipeptidy1 peptidase ( DPP ) -4 inhibitor . This study aim evaluate efficacy safety SP2086 monotherapy patient Type 2 Diabetes Mellitus Metformin monotherapy Who Have Inadequate Glycemic Control treat diet exercise 3 month</brief_summary>
	<brief_title>Efficacy Safety SP2086 Monotherapy Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients diagnose type 2 diabetes mellitus Patients treat diet/exercise least 3 month 7.5 % ≤HbA1C ≤11.0 % screening,7.0 % ≤HbA1C ≤10.5 % runin Patient history type 1 diabetes mellitus Patient history ketoacidosis Patient history severe unconscious hypoglycemosis Patient history acute chronic pancreatitis pancreatic injury may lead high risk pancreatitis Patient history decompensated heart failure ( NYHA class III IV ) , unstable angina , stroke transient ischemic attack , myocardial infarction , persistence clinical Patient history history hypertension , antihypertensive treatment , systolic blood pressure ≥ 160 mmHg diastolic blood pressure ≥ 100 mmHg Patient severe liver kidney disease , alanine aminotransferase &gt; 2×UNL , Aspartate Aminotransferase &gt; 2×upper normal limit ( UNL ) ；total bilirubin &gt; 2×UNL； creatinine &gt; 1.5 mg/dL ( Male,132.6μmol/L ) ， &gt; 1.4 mg/dL ( Female，123.8μmol/L ) Patient severe chronic gastrointestinal disease therapy may affect drug absorption , gastrointestinal surgery Patient severe haematological disease diseases lead hemolyze red blood cell unstable ( malaria、haemolytic anaemia eg . ) Patient endocrine disease , example hyperthyroidism、hypothyroidism、hypercortisolism、multiple endocrine neoplasia Patient history malignancy Patient history alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>SP2086</keyword>
	<keyword>Phase III</keyword>
	<keyword>Monotherapy</keyword>
</DOC>